Figure 6: Circulating concentration of (A & B) ALT (IU/L), (C
& D) miR-122 (fM) and (E & F) K18 (U/L) over the course of treatment
(weeks) for two cases who developed DILI as pre-defined as
>x3 ULN ALT in the presence of symptoms or >x5
ULN in absence of symptoms (Aithal et al. , 2011). Case 1 (A, C &
E); Case 2 (B, D & F).